Antigen binding molecules targeting SARS-CoV-2
AssigneeGenerate Biomedicines, Inc.
InventorsFrancesco Borriello, Alexis Hiram Ramos
Life of this patent
Estimating the term…
Abstract
The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).
Claims30
A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike) comprising:
- a) a heavy chain variable domain (VH) that comprises a heavy chain complementarity-determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:77, a HCDR2 comprising the amino acid sequence of SEQ ID NO:80, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:91;
- and
- b) a light chain variable domain (VL) that comprises a light chain complementarity-determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:133, a LCDR2 comprising the amino acid sequence of SEQ ID NO:141, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:144, wherein the polypeptide is an antibody or an antigen-binding fragment thereof.
A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike) comprising:
- a) a heavy chain variable domain (VH) that comprises a heavy chain complementarity-determining region (HCDR) 1 consisting of the amino acid sequence of SEQ ID NO:77, a HCDR2 consisting of the amino acid sequence of SEQ ID NO:80, and a HCDR3 consisting of the amino acid sequence of SEQ ID NO:91;
- and
- b) a light chain variable domain (VL) that comprises a light chain complementarity-determining region (LCDR) 1 consisting of the amino acid sequence of SEQ ID NO:133, a LCDR2 consisting of the amino acid sequence of SEQ ID NO:141, and a LCDR3 consisting of the amino acid sequence of SEQ ID NO:144, wherein the polypeptide is an antibody or an antigen-binding fragment thereof.
Dependencies are inferred from the claim text.